

Cyient DLM

Estimate change	
TP change	
Rating change	

Bloomberg	CYIENTDL IN
Equity Shares (m)	79
M.Cap.(INRb)/(USDb)	81.8 / 0.9
52-Week Range (INR)	1061 / 265
1, 6, 12 Rel. Per (%)	17/222/143
12M Avg Val (INR M)	366

Financials & Valuations (INR b)

Y/E Mar	FY27E	FY28E	FY29E
Sales	16.6	21.6	28.0
EBITDA	1.6	2.7	3.6
Adj. PAT	0.9	1.7	2.5
EBITDA Margin (%)	9.9	12.5	13.0
Cons. Adj. EPS (INR)	10.9	21.6	31.0
EPS Gr. (%)	51.8	97.5	43.8
BV/Sh. (INR)	140.7	162.3	193.4

Ratios

Net D:E	-0.3	-0.3	-0.3
RoE (%)	8.1	14.2	17.5
RoCE (%)	9.1	14.8	17.8

Valuations

P/E (x)	94	48	33
EV/EBITDA (x)	48	29	21

Shareholding pattern (%)

As on	Sep-26	Jun-26	Sep-25
Promoter	52.1	52.1	52.1
DII	27.2	29.2	28.7
FII	2.4	0.3	2.2
Others	18.3	18.5	17.0

Note: FII includes depository receipts

CMP: INR1,030

TP: INR1,320 (+28%)

Buy

Growth momentum intact; margins reflect upfront investments

Operating performance below our estimates

- Cyient DLM (CYIENTDL)'s 2QFY27 consol. revenue grew 27% YoY to INR3.9b, largely aided by a 61%/2.5x YoY growth in the aerospace/ MedTech segments. EBITDA margin contracted 130bp YoY to 8.7%, because of gross margin compression due to the expensing of product development costs.
- We believe CYIENTDL's growth story remains on track, supported by a record order book of INR28.1b (+23% YoY), continued aerospace momentum and a rising box-build contribution (37% in 2QFY27 vs. 25% in 2QFY26). However, upfront growth investments will keep FY27 EBITDA margins in the range of 9-10%. The sales and marketing platform is now in place to support a larger revenue base, positioning the company for operating leverage and double-digit margins from FY28 (refer to Exhibit 7). Beyond this, four Electronic Products programs worth a potential ~USD1b over 7–9 years offer a substantial growth opportunity from FY30.
- Factoring in revised EBITDA margin assumptions, we cut our earnings estimates by 16% for FY27 while maintaining our FY28/FY29 earnings estimates. We expect a CAGR of 30%/41%/63% in revenue/EBITDA/adj. PAT over FY26–29. **We reiterate our BUY rating on the stock with a TP of INR1,320 (based on 50x Sep'28 EPS, implying a 0.8x PEG ratio).**

Strong revenue growth supported by a record order book

- CYIENTDL's consol. revenue grew 27% YoY to INR3.3b (in line). Revenue from Aerospace/Defense/MedTech grew 61%/11%/2.5x YoY, while revenue from Industrial/Auto & others declined 41%/86% YoY.
- The company's order backlog expanded 23% YoY to INR28b, driven by a strong order intake of ~INR6.1b in 2QFY27 (vs. an avg. order intake of INR4.7b over the last eight quarters).
- Gross margin contracted 380bp to 37.4% due to prototype development, which led to an EBITDA margin contraction of 130bp YoY to 8.7% (est. 10.5%). EBITDA grew 10% YoY to INR342m (est. INR412m). Adj. PAT was up 26% YoY to INR158m (est. INR234m; PAT is adjusted for a gain of INR182m on the fair valuation of the earnout liability).
- In 1HFY27, CYIENTDL's revenue/EBITDA/APAT grew 30%/30%/83% to INR7.7b/INR733m/INR367m.
- CFO dipped 90% YoY in 1HFY27 to INR142m due to higher raw material build-up amid the ongoing West Asia crisis. As of Sep'26, its net cash stood at INR226m vs. INR187as of Mar'26.
- NWC as of Jun'26 stood at 153 days (vs. 161 in 1QFY27 and 139 in 2QFY26).

Highlights from the management commentary

- **Guidance/Outlook:** Revenue growth of more than 30% YoY in 2HFY27, with momentum continuing into FY28. Quarterly order intake is expected to remain around INR6b-plus over the next two quarters. FY27 EBITDA margin guidance stands at 9–10%, with a recovery to double digits from FY28.
- **Electronics Products: The B2S business has been renamed Electronic Products,** under which CYIENTDL is developing four major programs with a potential value of ~USD1b over 7–9 years. This business is currently excluded from the reported order book. The initial production could commence in FY29, followed by a meaningful ramp-up from FY30.
- **Margin expansion:** Near-term margin pressure reflects upfront investments in sales, marketing and product development, with development costs fully expensed rather than capitalized. Revenue growth and better cost absorption should support margin recovery from FY28, progressing from the core business margin framework of 9–11% toward 11–13% as the company scales into adjacent segments. A rising contribution from Electronic Products and differentiated platforms could further lift margins to 13–18% from FY30 onward.

Valuation and view

- CYIENTDL sustained strong growth in 2QFY27, with a record order book of INR28.1b reinforcing visibility for 2HFY27 and beyond. We believe the company is entering a multi-year growth phase, supported by a) continued aerospace momentum, b) increasing box-build contribution and semiconductor equipment ramp-up, and c) four Electronic Products programs, which are expected to scale meaningfully from FY30.
- We estimate a CAGR of 30%/41%/63% in revenue/EBITDA/adj. PAT over FY26–29E. **We reiterate our BUY rating on the stock with a TP of INR1,320 (50x Sep’28 EPS, implying a 0.8x PEG ratio).**


Consolidated - Quarterly Earnings

(INR m)

Y/E March	FY26				FY27				FY26	FY27E	FY27E	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	%
Gross Sales	2,784	3,106	3,033	3,691	3,738	3,931	4,004	4,909	12,615	16,582	3,930	0
YoY Change (%)	8.0	-20.2	-31.7	-13.8	34.3	26.5	32.0	33.0	-17.0	31.4	26.5	
Total Expenditure	2,534	2,794	2,724	3,260	3,346	3,589	3,636	4,367	11,312	14,939	3,517	
EBITDA	251	312	309	431	392	342	368	541	1,302	1,643	412	-17
Margins (%)	9.0	10.0	10.2	11.7	10.5	8.7	9.2	11.0	10.3	9.9	10.5	
Depreciation	105	106	108	109	111	114	114	114	428	453	111	
Interest	86	68	61	56	61	61	25	23	272	170	52	
Other Income	42	31	43	51	3	44	75	78	167	200	63	
PBT before EO expense	101	169	183	317	222	211	304	483	770	1,220	312	
Extra-Ord expense	0	-196	34	0	0	-182	0	0	-162	-182	0	
PBT	101	365	149	317	222	393	304	483	932	1,402	312	
Tax	26	43	37	92	59	53	93	148	199	353	78	
Rate (%)	26.1	11.9	24.6	29.2	26.7	13.5	30.6	30.6	21.3	25.2	24.9	
Reported PAT	75	321	112	224	163	340	211	335	733	1,049	234	
Adj PAT	75	126	147	224	163	158	211	335	571	867	234	-33
YoY Change (%)	-29.6	-18.7	-13.0	-27.7	118.2	25.8	44.1	49.2	-22.7	51.8	86.4	
Margins (%)	2.7	4.0	4.8	6.1	4.4	4.0	5.3	6.8	4.5	5.2	6.0	


Key exhibits

Exhibit 1: Consolidated order book trend




Source: Company, MOFSL

Exhibit 2: Consolidated revenue trend




Source: Company, MOFSL

Exhibit 3: Consolidated EBITDA trend




Source: Company, MOFSL

Exhibit 4: Consolidated adj. PAT trend




Source: Company, MOFSL

Exhibit 5: Product-wise revenue mix




Source: Company, MOFSL

Exhibit 6: End-user industry-wise revenue mix



Source: Company, MOFSL


Exhibit 7: Strategic pivot: Path from ~9–11% to ~13–18% margins



Source: Company, MOFSL


Exhibit 8: Global EMS market: An ~USD1t opportunity in the making

EMS spend compounds from ~\$650 Bn toward ~\$1 Tn; AI infrastructure, semicap and robotics are the fastest-growing pools



Source: Company, MOFSL

Exhibit 9: Quarterly working capital days trend



Source: Company, MOFSL



Highlights from the management commentary

Guidance and Outlook

- Management guided for FY27 EBITDA margins of ~9–10%, with a return to double-digit margins from FY28.
- The near-term margin pressure reflects investments in sales, marketing and product development, while revenue growth and improved cost absorption are expected to support recovery.
- Management expects 2HFY27 revenue growth to exceed 30% YoY, supported by the strong order backlog.
- Management expects the growth momentum to continue into FY28. Quarterly growth may fluctuate depending on material availability, customer-site readiness and program execution schedules.
- Quarterly order intake is expected to remain around INR6b-plus over the next two quarters, broadly sustaining the recent pace of inflows.
- The existing order book has a typical execution horizon of 18–24 months, with only a limited number of orders extending beyond two years.
- Electronic Products program could begin production in FY29, with a more meaningful production ramp from FY30 onward. Semiconductor capital equipment is already contributing to the company's revenue.
- Clearer updates on AI/data-center infrastructure and robotics are expected by FY27-end.
- Management's strategic margin framework progresses from 9–11% for strengthening the core business to 11–13% during expansion and 13–18% during the longer-term product-led transformation.

Order book, order inflows and bid pipeline

- The quarterly book-to-bill ratio remained above 1.6x, supported by strong inflows from large original equipment manufacturers (OEMs).
- The company added three new customer logos during the quarter, expanding its customer base and creating opportunities for future business.
- Pipeline exceeding USD1b and unweighted pipeline was approximately USD1.5b.
- The historical bid-win ratio is approximately 40%, although conversion depends on the stage and maturity of individual opportunities. Some prospects remain at the lead-generation or qualification stage.
- Management discussed USD400–500m of potential order intake from pipeline conversion
- The pipeline is continuously replenished as opportunities convert into orders and new prospects are added.
- Only part of the ~USD1b Electronic Products opportunity is included in the bid pipeline.
- Individual customer orders have varying delivery schedules, including three, six and twelve months, while the broader backlog has an execution horizon of 18–24 months.

Margin drivers and operating leverage

- Management clarified that the main reason for lower FY27 EBITDA margins is the expanded sales and marketing cost base, rather than weaker underlying business quality.

- Gross margin and contribution margin were described as significantly higher in FY27 year to date than in FY26 excluding the prototyping development cost.
- Quarterly revenue mix affected profitability, but management characterized these movements as normal for a high-mix, low-volume manufacturing business.
- The company has added sales personnel, senior leadership, marketing capabilities and a chief growth officer. These costs are fully reflected in the profit and loss account, while the associated revenue benefits are still developing.
- Management does not intend to add net new sales and marketing costs until quarterly revenue at least doubles,
- Margin recovery is therefore expected to come primarily from higher revenue absorbing the existing cost base, rather than the complete removal of these expenses.
- Management described investment-related margin pressure at approximately 100–150bp.

Product-development expenditure and accounting

- Product-development expenditure, including prototypes and engineering work, is being expensed rather than capitalized.
- Development costs precede commercial revenue, creating a timing difference between expenditure recognized today and benefits expected in later periods.
- Product-development investment has been ongoing for several quarters and was not initiated only in 2QFY27.
- Product-development investment will continue even as further sales and marketing additions are restricted.

Electronic Products: ~USD1b across four programs

- The build-to-specification offering has been renamed “Electronic Products” to reflect the company’s involvement across the product lifecycle.
- Capabilities span product architecture, detailed engineering, embedded hardware and software integration, prototyping, testing, qualification, industrialization and transition to volume production.
- The company is working on four major programs with an aggregate potential value close to USD1bn over approximately seven to nine years. This represents a program value over their respective lifetimes, rather than an annual revenue.
- Some customer contracts have already been signed, while others are expected to be signed as programs reach the appropriate development stage.
- These program values are not currently included in the reported order book. They are expected to enter the backlog as development progresses and orders materialize.
- Engineering work is underway, with some products undergoing customer-site testing and others in internal testing.
- Initial production could begin in FY29, followed by fuller production and a more meaningful ramp from FY30 onward.
- Electronic Products remains a priority for investment, given the long manufacturing lifecycles and potential to deepen strategic customer relationships.

Other

- For the eVTOL program, management confirmed that contracts have been signed, but the associated opportunity is not yet included in the order book.
- Engineering design, prototype development and testing must be completed before the program moves into production. Management referred to production in FY29, with CYIENTDL's revenue emerging around or after that transition.
- For the Honeywell engagement discussed during the call, management confirmed that the scope is build-to-print. Several prototypes have been manufactured and are undergoing testing.
- Modifications and engineering changes have extended the time required to transition the Honeywell program into serial production.
- Semiconductor capital equipment has already generated revenue during the past two quarters, with management expecting further ramp-up and growth in subsequent quarters.
- AI/data-center infrastructure and robotics remain exploratory opportunities, with clearer updates on identified opportunities and the pipeline expected by FY27-end.
- Potential AI/data-center applications include box-build solutions, cables and cooling controls, drawing on existing capabilities in high-reliability manufacturing, systems integration and power electronics.

Valuation and view

- CYIENTDL sustained strong growth in 2QFY27, with a record order book of INR28.1b reinforcing visibility for 2HFY27 and beyond. We believe the company is entering a multi-year growth phase, supported by a) continued aerospace momentum, b) increasing box-build contribution and semiconductor equipment ramp-up, and c) four Electronic Products programs, which are expected to scale meaningfully from FY30.
- We estimate a CAGR of 30%/41%/63% in revenue/EBITDA/adj. PAT over FY26-29E. **We reiterate our BUY rating on the stock with a TP of INR1,320 (50x Sep'28 EPS, implying a 0.8x PEG ratio).**

Exhibit 10: Our revised estimates

Earnings change (INR m)	Old			New			Change		
	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E
Revenue	16,399	21,319	27,715	16,582	21,556	28,023	1%	1%	1%
EBITDA	1,804	2,665	3,603	1,643	2,695	3,643	-9%	1%	1%
Adj. PAT	1,038	1,691	2,433	867	1,713	2,463	-16%	1%	1%

Financials and valuations

Consolidated - Income Statement

(INRm)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E	FY29E
Total Income from Operations	6,280	7,205	8,320	11,919	15,196	12,615	16,582	21,556	28,023
Change (%)	37.4	14.7	15.5	43.2	27.5	-17.0	31.4	30.0	30.0
RM Cost	4,953	5,440	6,452	9,200	11,082	7,522	10,306	13,580	17,655
Employees Cost	469	517	647	1,174	1,862	2,251	2,744	2,910	3,643
Other Expenses	399	409	344	435	800	1,539	1,889	2,371	3,083
Total Expenditure	5,821	6,365	7,442	10,809	13,745	11,312	14,939	18,862	24,380
% of Sales	92.7	88.3	89.4	90.7	90.4	89.7	90.1	87.5	87.0
EBITDA	460	840	878	1,110	1,452	1,302	1,643	2,695	3,643
Margin (%)	7.3	11.7	10.6	9.3	9.6	10.3	9.9	12.5	13.0
Depreciation	185	193	194	223	341	428	453	476	513
EBIT	275	647	684	887	1,111	875	1,190	2,219	3,130
Int. and Finance Charges	208	220	315	344	375	272	170	150	80
Other Income	89	79	63	278	262	167	200	220	242
PBT bef. EO Exp.	156	507	432	821	997	770	1,220	2,289	3,292
EO Items	0	0	0	0	80	-162	-182	0	0
PBT after EO Exp.	156	507	432	821	917	932	1,402	2,289	3,292
Total Tax	38	109	114	209	236	199	353	576	829
Tax Rate (%)	24.2	21.6	26.5	25.5	25.8	21.3	25.2	25.2	25.2
Minority Interest	0	0	0	0	0	0	0	0	0
Reported PAT	118	398	317	612	681	733	1,049	1,713	2,463
Adjusted PAT	118	398	317	612	739	571	867	1,713	2,463
Change (%)	-276.3	236.0	-20.2	92.9	20.8	-22.7	51.8	97.5	43.8
Margin (%)	1.9	5.5	3.8	5.1	4.9	4.5	5.2	7.9	8.8

Consolidated - Balance Sheet

(INRm)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E	FY29E
Equity Share Capital	14	14	529	793	793	794	794	794	794
Total Reserves	363	757	1,450	8,297	8,701	9,327	10,377	12,090	14,553
Net Worth	377	771	1,979	9,090	9,494	10,121	11,170	12,883	15,347
Total Loans	2,790	3,369	3,145	1,336	2,438	1,061	561	61	61
Deferred Tax Liabilities	-51	-39	0	0	0	0	0	0	0
Capital Employed	3,116	4,101	5,123	10,425	11,932	11,182	11,732	12,944	15,408
Gross Block	2,650	2,668	2,750	3,285	4,513	4,961	5,203	5,612	6,053
Less: Accum. Deprn.	824	977	1,171	1,394	1,734	2,162	2,615	3,090	3,604
Net Fixed Assets	1,826	1,692	1,579	1,891	2,779	2,799	2,589	2,521	2,450
Goodwill on Consolidation	30	30	30	30	681	749	749	749	749
Capital WIP	23	34	13	10	56	21	229	271	279
Total Investments	3	3	895	662	309	302	302	302	302
Curr. Assets, Loans&Adv.	4,517	5,971	8,529	13,440	13,115	12,550	14,286	17,326	22,320
Inventory	1,555	2,696	4,251	4,642	5,713	6,473	4,941	6,139	7,981
Account Receivables	2,264	1,523	1,617	2,259	3,474	3,073	4,303	5,594	7,272
Cash and Bank Balance	342	1,218	1,676	5,366	2,878	1,258	3,205	3,204	3,962
Loans and Advances	357	534	985	1,173	1,050	1,746	1,838	2,389	3,106
Curr. Liability & Prov.	3,284	3,629	5,924	5,607	5,007	5,240	6,424	8,225	10,692
Account Payables	1,928	1,932	2,853	3,200	2,499	2,733	3,388	4,279	5,562
Other Current Liabilities	1,262	1,564	2,973	2,297	2,326	2,359	2,819	3,665	4,764
Provisions	93	134	98	110	182	147	217	282	366
Net Current Assets	1,233	2,342	2,605	7,832	8,107	7,311	7,863	9,101	11,628
Appl. of Funds	3,116	4,101	5,123	10,425	11,932	11,182	11,732	12,944	15,408

Financials and valuations

Ratios

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E	FY29E
Basic (INR)									
EPS	1.5	5.0	4.0	7.7	9.3	7.2	10.9	21.6	31.0
Cash EPS	3.8	7.4	6.4	10.5	13.6	12.6	16.6	27.6	37.5
BV/Share	4.7	9.7	24.9	114.5	119.6	127.5	140.7	162.3	193.4
Valuation (x)									
P/E	691.0	205.6	257.7	133.6	110.6	143.1	94.2	47.7	33.2
Cash P/E	269.9	138.5	159.8	97.9	75.7	81.8	61.9	37.3	27.5
P/BV	217.1	106.0	41.3	9.0	8.6	8.1	7.3	6.3	5.3
EV/Sales	13.4	11.6	10.0	6.5	5.4	6.4	4.8	3.6	2.8
EV/EBITDA	183.2	99.9	94.8	70.0	56.0	62.5	48.0	29.1	21.3
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
FCF per share	0.9	5.1	5.8	-13.1	-14.2	1.2	30.4	5.4	7.5
Return Ratios (%)									
RoE	37.3	69.3	23.1	11.1	8.0	5.8	8.1	14.2	17.5
RoCE	8.5	15.6	11.9	11.2	9.1	7.1	9.1	14.8	17.8
RoIC	9.1	18.1	18.7	19.1	12.6	7.5	10.1	19.3	23.4
Working Capital Ratios									
Fixed Asset Turnover (x)	2.4	2.7	3.0	3.6	3.4	2.5	3.2	3.8	4.6
Asset Turnover (x)	2.0	1.8	1.6	1.1	1.3	1.1	1.4	1.7	1.8
Inventory (Days)	139	143	196	176	171	296	175	165	104
Debtor (Days)	82	96	69	59	69	95	95	95	95
Creditor (Days)	115	130	135	120	94	127	120	115	72
Leverage Ratio (x)									
Current Ratio	1.4	1.6	1.4	2.4	2.6	2.4	2.2	2.1	2.1
Interest Cover Ratio	1.3	2.9	2.2	2.6	3.0	3.2	7.0	14.8	39.1
Net Debt/Equity	6.5	2.8	0.7	-0.4	0.0	0.0	-0.3	-0.3	-0.3

Consolidated - Cash Flow Statement

(INRm)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E	FY29E
OP/(Loss) before Tax	118	398	317	821	917	932	1,220	2,289	3,292
Depreciation	185	193	194	223	341	428	453	476	513
Interest & Finance Charges	171	175	267	344	375	272	-30	-70	-162
Direct Taxes Paid	1	-62	-168	-195	-257	-224	-353	-576	-829
(Inc)/Dec in WC	-200	-329	-229	-1,676	-1,976	-491	1,395	-1,239	-1,769
CF from Operations	275	375	381	-483	-600	916	2,685	879	1,045
Others	74	111	158	-222	-24	-377	182	0	0
CF from Operating incl EO	349	486	539	-705	-624	539	2,867	879	1,045
(Inc)/Dec in FA	-274	-77	-76	-338	-500	-447	-450	-450	-450
Free Cash Flow	75	409	463	-1,043	-1,124	92	2,417	429	595
(Pur)/Sale of Investments	0	0	-892	0	0	0	0	0	0
Others	265	-247	-450	-3,940	1,767	2,083	200	220	242
CF from Investments	-9	-324	-1,418	-4,277	1,267	1,636	-250	-230	-208
Issue of Shares	0	0	889	7,000	0	1	0	0	0
Inc/(Dec) in Debt	-336	534	-4	-1,647	323	-1,512	-500	-500	0
Interest Paid	-92	-73	-145	-192	-644	-235	-170	-150	-80
Dividend Paid	0	0	0	0	0	0	0	0	0
Others	-232	0	-19	-371	-266	-129	0	0	0
CF from Fin. Activity	-660	461	721	4,790	-587	-1,876	-670	-650	-80
Inc/Dec of Cash	-320	622	-158	-193	55	299	1,947	0	758
Opening Balance	662	342	1,218	1,676	5,366	2,878	1,258	3,205	3,204
Other cash & cash equivalent	0	254	616	3,883	-2,544	-1,919	0	0	
Closing Balance	342	1,218	1,676	5,366	2,878	1,258	3,205	3,204	3,962

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	> - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

MOFSL, its associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

In the past 12 months, MOFSL or any of its associates may have:

- received any compensation/other benefits from the subject company of this report
- managed or co-managed public offering of securities from subject company of this research report,
- received compensation for investment banking or merchant banking or brokerage services from subject company of this research report,
- received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.

- MOFSL and its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

- a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.
- (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement	Cyient DLM
Analyst ownership of the stock	No

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration

provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act of Singapore. Accordingly, if a Singapore person is not, or ceases to be, such an investor, they must immediately discontinue any use of this Report and inform MOCMSPL.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai - 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.